ReSure Sealant Pivotal Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01498224
Recruitment Status : Completed
First Posted : December 23, 2011
Last Update Posted : December 12, 2016
Information provided by (Responsible Party):
Ocular Therapeutix, Inc.

Brief Summary:
This is a randomized multicenter study to evaluate the safety and effectiveness of ReSure Sealant compared to sutures for preventing incision leakage within the first 7 days of cataract surgery.

Condition or disease Intervention/treatment Phase
Cataract Surgery Incision Leak Device: ReSure Sealant Procedure: Sutures Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 488 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: ReSure Sealant Pivotal Study
Study Start Date : December 2011
Actual Primary Completion Date : November 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Active Comparator: Suture
Suture application
Procedure: Sutures
Experimental: ReSure Sealant
Sealant application
Device: ReSure Sealant
Comparison of ReSure Sealant to suture(s)

Primary Outcome Measures :
  1. Proportion of eyes with any clear corneal incision/suture leakage as determined by positive Seidel test indicating fluid egress within first 7 days after surgery. [ Time Frame: Days 1-28 ]

Secondary Outcome Measures :
  1. Foreign Body Sensation [ Time Frame: Days 1-28 ]
  2. Best corrected visual acuity [ Time Frame: Day 1 ]
    Best corrected visual acuity worse than 20/40 at day 1

  3. Best corrected visual acuity [ Time Frame: Day 28 ]
    Best corrected visual acuity worse than 20/40 at 28 days

Other Outcome Measures:
  1. Presence of ReSure Sealant or suture(s) [ Time Frame: Day 28 ]
    Presence of ReSure Sealant or suture(s)at every follow-up visit

  2. Presence of blue colorant in ReSure Sealant [ Time Frame: Day 28 ]
    Presence of blue colorant in ReSure Sealant at every follow-up visit

  3. Device ease of use [ Time Frame: Day 0 ]
    Device ease of use during application

  4. Corneal edema at 1 day [ Time Frame: Day 1 ]
    Corneal edema at 1 day (moderate to severe stromal edema)

  5. Anterior chamber inflammation [ Time Frame: Day 1 ]
    Anterior chamber inflammation (defined as greater than or equal to grade 2+ anterior chamber cells) at day 1

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has a cataract and is expected to undergo clear cornea cataract surgery with phacoemulsification and implantation of posterior chamber intraocular lens
  • Subject must be 22 years of age or older

Exclusion Criteria:

  • Any intraocular inflammation in study eye or presence of ocular pain in operative eye at preoperative assessment
  • Previous corneal or retinal surgery or planned multiple procedures during cataract surgery.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01498224

United States, Florida
Levenson Eye Associates
Jacksonville, Florida, United States, 32204
Sponsors and Collaborators
Ocular Therapeutix, Inc.

Additional Information:
Responsible Party: Ocular Therapeutix, Inc. Identifier: NCT01498224     History of Changes
Other Study ID Numbers: OTX-11-002
First Posted: December 23, 2011    Key Record Dates
Last Update Posted: December 12, 2016
Last Verified: February 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Data is available on FDA website for approved PMA P130004

Keywords provided by Ocular Therapeutix, Inc.:
Cataract surgery

Additional relevant MeSH terms:
Lens Diseases
Eye Diseases